OrbiMed’s Gilead Sciences GILD Stock Holding History

OrbiMed’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200,000	Closed	-$18.5M	–	115
2024 Q4	$18.5M	Buy	+200,000	New	+$18M	0.38%	56
2019 Q3	–	Sell	-100,000	Closed	-$6.76M	–	129
2019 Q2	$6.76M	Buy	+100,000	New	+$6.58M	0.1%	99

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed's GILD Position: Q2 2026 in Review

OrbiMed sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 59,600 shares — an estimated $8.31M sold.

OrbiMed first reported a position in GILD in Q2 2013 and held it in 44 quarters. The position peaked at $401M in Q4 2014. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

OrbiMed reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 59,600 Gilead Sciences shares in Q2 2026, an estimated $8.31M.
OrbiMed first reported a position in Gilead Sciences in Q2 2013 and held it in 44 quarters.
OrbiMed's Gilead Sciences position peaked at $401M in Q4 2014.
2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.